- Home
- PHVS vs SRCE Comparison
PHVS vs SRCE Comparison
Compare PHVS & SRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- SRCE
- Stock Information
- Founded
- PHVS 2015
- SRCE 1863
- Country
- PHVS Switzerland
- SRCE United States
- Employees
- PHVS N/A
- SRCE N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- SRCE Major Banks
- Sector
- PHVS Health Care
- SRCE Finance
- Exchange
- PHVS Nasdaq
- SRCE Nasdaq
- Market Cap
- PHVS 1.3B
- SRCE 1.5B
- IPO Year
- PHVS 2021
- SRCE N/A
- Fundamental
- Price
- PHVS $24.30
- SRCE $63.37
- Analyst Decision
- PHVS Strong Buy
- SRCE Hold
- Analyst Count
- PHVS 5
- SRCE 3
- Target Price
- PHVS $35.60
- SRCE $72.00
- AVG Volume (30 Days)
- PHVS 123.2K
- SRCE 64.9K
- Earning Date
- PHVS 11-12-2025
- SRCE 10-23-2025
- Dividend Yield
- PHVS N/A
- SRCE 2.37%
- EPS Growth
- PHVS N/A
- SRCE 10.56
- EPS
- PHVS N/A
- SRCE 5.70
- Revenue
- PHVS N/A
- SRCE $391,814,000.00
- Revenue This Year
- PHVS N/A
- SRCE $17.85
- Revenue Next Year
- PHVS N/A
- SRCE $1.85
- P/E Ratio
- PHVS N/A
- SRCE $11.26
- Revenue Growth
- PHVS N/A
- SRCE 6.91
- 52 Week Low
- PHVS $11.51
- SRCE $52.14
- 52 Week High
- PHVS $26.33
- SRCE $68.13
- Technical
- Relative Strength Index (RSI)
- PHVS 59.77
- SRCE 51.48
- Support Level
- PHVS $23.20
- SRCE $62.09
- Resistance Level
- PHVS $24.75
- SRCE $64.39
- Average True Range (ATR)
- PHVS 1.29
- SRCE 1.09
- MACD
- PHVS 0.07
- SRCE -0.18
- Stochastic Oscillator
- PHVS 84.81
- SRCE 34.32
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About SRCE 1st Source Corporation
1st Source Corp, along with its subsidiary, offers banking services. The bank provides Commercial, Agricultural, and Real Estate Loans, which are given to privately owned business clients mainly located within the regional market areas, Consumer Services that consist of the full range of consumer banking products and services, Trust and Wealth Advisory Services, and Insurance services to individuals and business clients. Its Specialty Finance Group offers financing services for construction equipment, new and pre-owned private and cargo aircraft, and various vehicle types for fleet purposes.